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Transmission patterns of HIV-1 
non-R5 strains in Poland
Joanna Smoleń-Dzirba1, Magdalena Rosińska  2, piotr Kruszyński1, Janusz Janiec2, 
Mariusz Cycoń  1, Jolanta Bratosiewicz-Wąsik3, Marek Beniowski4, Monika Bociąga-Jasik5, 
Elżbieta Jabłonowska6, Bartosz Szetela  7 & Tomasz J. Wąsik1
HIV-1 env sequencing enables predictions of viral coreceptor tropism and phylogenetic investigations of 
transmission events. The aim of the study was to estimate the contribution of non-R5 strains to the viral 
spread in Poland. Partial proviral env sequences were retrieved from baseline blood samples of patients 
with newly diagnosed HIV-1 infection between 2008–2014, including 46 patients with recent HIV-1 
infection (RHI), and 246 individuals with long-term infection (LTHI). These sequences were subjected 
to the genotypic coreceptor tropism predictions and phylogenetic analyses to identify transmission 
clusters. Overall, 27 clusters with 57 sequences (19.5%) were detected, including 15 sequences (26.3%) 
from patients with RHI. The proportion of non-R5 strains among all study participants was 23.3% 
(68/292), and was comparable between patients with RHI and LTHI (11/46, 23.9% vs 57/246, 23.2%; 
p = 1.000). All 11 patients with non-R5 strains and RHI were men having sex with men (MSM). Among 
these patients, 4 had viral sequences grouped within phylogenetic cluster with another sequence of 
non-R5 strain obtained from patient with LTHI, indicating potential acquisition of non-R5 HIV-1 for at 
least 4/46 (8.7%) patients with RHI. We were unable to confirm the contribution of patients with RHI to 
the forward transmission of non-R5 strains, but a relatively high proportion of non-R5 strains among 
them deserves attention due to the limited susceptibility to CCR5 antagonists.
Human immunodeficiency virus type 1 (HIV-1) surface glycoprotein (gp120), a product of viral env gene, plays 
a key role in cell entry, viral tropism, pathogenesis, vulnerability to the host immune response and susceptibility 
to the entry inhibitors such as maraviroc1–3. The third variable loop (V3) of the gp120 contributes to the HIV-1 
entrance into target cells by binding to the cell CD4 receptor followed by attachment to either the CCR5 or 
CXCR4 coreceptor molecules1,4. Viruses that during cell entry exclusively use the CCR5 or CXCR4 coreceptor 
are termed R5 or X4, respectively, whereas those that can use both coreceptors are described as R5X4 viruses. 
Usually, R5 viruses are associated with HIV-1 transmission and predominate at early phases of infection, while 
X4 or R5X4 (non-R5) viruses emerge as infection develops1, and are linked to accelerated disease progression and 
decline of CD4+ T-cell counts5–7. Although several mechanisms of selection against transmission of X4 viruses 
were proposed8,9, it has been reported that also CXCR4-using HIV-1 variants can be transmitted to a new host, 
e.g. to individuals lacking functional CCR5 receptor10. The proportion of infections with CXCR4-using strains 
investigated among patients with early infection stages, suggesting transmission of X4 variants, ranged from 3% 
to 26% depending on the population examined and method used to assess viral coreceptor tropism5,11–20.
To date, studies on HIV-1 coreceptor tropism in Poland were restricted to the northern geographic region 
and were performed among patients with long-term HIV-1 infection and experience of antiretroviral therapy21, 
and among treatment-naïve persons with a new HIV-1 diagnosis22. In the second group the overall prevalence of 
non-R5 strains was 15.5% or 27.8% depending on the interpretation criteria used in genotypic tropism test, and 
an increase in the frequency of non-R5 strains during the study period was observed, suggesting either increase 
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of late HIV-1 diagnoses or putative transmission of CXCR4-using viruses in the local population22. Nevertheless, 
these studies did not allow to evaluate the rate of transmission of non-R5 strains, while this information would be 
useful for reasonable planning of treatment programs, especially in the context of the strong push to identify early 
HIV-1 infections, and the potential role of CCR5 antagonists in pre-exposure prophylaxis23.
The analysis of HIV-1 env gene sequences enables not only genotypic predictions of viral coreceptor tropism, 
but also allows for phylogenetic investigations aimed at detection of transmission clusters, which can facilitate the 
understanding of the epidemiological links. Thus, it is possible to study the contribution of patients with specified 
characteristics to HIV-1 transmission, and e.g. confirm the forward transmission of non-R5 strains or viral spread 
from patients at different infection stages24–26.
To obtain a more complete picture of the HIV-1 epidemics in Poland, analyses of env gene viral sequences 
from patients with new HIV-1 diagnosis established in the years 2008–2014 and known proportion of recent 
HIV-1 infections, were performed. Investigations included viral and host characteristics associated with core-
ceptor tropism and identified transmission clusters, in order to trace the spread of non-R5 HIV-1 strains and 
assess the contribution of recent infections to the Polish HIV-1 epidemic.
Results
Patients and virus characteristics. The characteristics of the 292 patients included in the analysis are 
presented in Table 1. All study participants were of Polish origin and were naïve for antiretroviral therapy. Among 
them there were 46 (15.8%) patients with recent HIV-1 infection (RHI), and 246 (84.2%) individuals with long-
term HIV-1 infection (LTHI). Sexual contacts between men were the most frequently reported transmission 
route (199/292; 68.2%), with the proportion not significantly different in groups with dissimilar duration of 
infection (RHI: 35/46, 76.1% vs LTHI: 164/246, 66.7%; p = 0.232). Similarly, there were no statistical differences 
between patients with RHI and LTHI with respect to other transmission routes, sex, age, and CCR5 Δ32 genotype 
status. Although patients recruited in Chorzów predominated in the study (130/292; 44.5%), patients recruited 
in Wrocław constituted the most numerous group among the individuals with RHI (21/46; 45.7%; p = 0.007). A 
statistically significant difference between individuals with recent and long-term HIV-1 infection was observed 
for median baseline CD4+ T-lymphocyte count (RHI: 564 vs LTHI: 396 cells/µl; p = 0.002), and proportion of 
patients with higher CD4+ T-lymphocyte count at diagnosis (>500 cells/μl – RHI: 26/43, 60.5% vs LTHI: 79/229, 
34.5%; p = 0.002). A baseline HIV-1 viral load, usually high at early infection stages, unexpectedly was signifi-
cantly higher among patients with LTHI (RHI: 4.19 vs LTHI: 4.51 log copies/ml; p = 0.045) (Table 1). We note 
however, that the average delay between the diagnosis and the sample collection in our study was 32 days, which 
means that in many cases of recent infection we may have captured an already stabilised viral load, rather than 
the initial peak.
According to the subtype analysis of 292 HIV-1 env sequences, the majority of patients were infected with 
subtype B (279; 95.6%) (Table 2). Among 13 patients with non-B subtype infection, there were 8 individuals har-
bouring sub-subtype A6 (2.7%), 3 persons with CRF50_A1D infection, and remaining 2 persons were infected 
with CRF02_AG and sub-subtype F1, respectively. Strains of sub-subtype A6 were detected in all four diagnostic 
centres, and among patients who acquired HIV-1 infection either through same sex contact between men (n = 5) 
or heterosexual contact (n = 1) or via drug injections (n = 2), while CRF50_A1D strains were found exclusively 
in Kraków, among patients with homosexual (n = 2) or heterosexual (n = 1) route of transmission. CRF02_AG 
and F1 were identified in men who have sex with men (MSM) recruited in Kraków and Wrocław, respectively. 
There were no statistically significant differences regarding subtype frequency between patients with recent and 
long-term HIV-1 infection (p = 0.176). However, non-B subtypes were significantly less frequent among patients 
diagnosed in Chorzów than in other cities (Chorzów: 2/130, 1.5% vs other diagnostics centres: 11/162, 6.8% 
p = 0.043), and more frequent among patients diagnosed in Kraków (Kraków: 5/41, 12.2% vs other diagnostics 
centres: 8/251, 3.2% p = 0.023).
The median frequency of ambiguous nucleotides in the analysed env sequences was significantly lower among 
patients with RHI than those with LTHI (RHI: 0% (0–0) vs LTHI: 0.14% (0–0.41); p < 0.001) (Table 2).
Coreceptor usage. The frequency of non-R5 strains among all patients included in the study was 23.3% 
(68/292) when the geno2pheno 10% FPR cut-off was applied for the subtype B sequences and PhenoSeq results 
were used for non-B subtypes (Table 2). The same frequency of non-R5 variants was observed for all sequences 
analysed with geno2pheno 10% FPR only. Applying geno2pheno FPR cut-off values of 15% and 20% resulted in 
the frequency of non-R5 strains as high as 34.9% (102/292) and 45.5% (133/292), respectively. With the more 
restrictive 5.75% FPR cut-off the frequency of non-R5 strains was decreased to 9.6% (28/292). There were no 
significant differences between persons with RHI and LTHI regarding the frequency of the non-R5 strains, 
and values of geno2pheno FPRs were comparable between patients with recent and long-term HIV-1 infection 
(p = 0.578) (Table 2).
Comparison of all patients harbouring non-R5 and R5 strains predicted by geno2pheno 10% FPR for the 
subtype B sequences and PhenoSeq for non-B subtypes revealed no significant differences with regard to sex, age, 
city of diagnosis, CCR5 Δ32 genotype, median viral load, and HIV-1 subtype (Table 3). Similarly, no significant 
differences were seen between non-R5 and R5 strains with respect to the number of ambiguous nucleotides and 
deduced ambiguous amino acids in V3 coding region. When the same comparisons were performed exclusively 
among persons with RHI, again the lack of significant differences between non-R5 and R5 strains was observed. 
A trend toward a higher proportion of MSM among patients with non-R5 strains in comparison with those har-
bouring R5 strains, was observed when all samples were tested (p = 0.054). This trend reached the level of statis-
tical significance when analysis was restricted to the samples obtained from patients with recent HIV-1 infection 
only (p = 0.044) (Table 3).
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Transmission clusters. Among 292 HIV-1 sequences there were 27 transmission clusters containing 57 
sequences (19.5%) identified (Table 4, Fig. 1). These clusters included from 2 to 3 sequences, with the major-
ity of clusters containing only 2 sequences (24/27, 88.9%). The differences between patients with clustered and 
non-clustered HIV-1 sequences regarding the proportion of individuals of different sex, age, city of HIV-1 
diagnosis, CCR5 Δ32 genotype, or infected with different HIV-1 subtypes or strains of different tropism were 
not significant, although a trend toward a higher prevalence of men within the group of patients with clustered 
sequences was noticed (p = 0.058) (Table 4). Patients with heterosexual transmission route were exclusively 
infected with viruses of non-clustered env sequences (p < 0.001), while patients for whom the route of trans-
mission was unknown were more frequently represented among individuals with clustered HIV-1 sequences 
than among those with non-clustered sequences (p = 0.015). Similarly, higher proportion of MSM was observed 
within the group of clustered HIV-1 sequences, but the difference was not statistically significant (clustered: 
44/57, 77.2% vs non-clustered: 155/235, 66.0%; p = 0.115). While the majority of clustered HIV-1 sequences were 
obtained from patients with LTHI (42/57, 73.7%), the proportion of sequences from persons with RHI was higher 
among clustered sequences than among non-clustered sequences (clustered: 15/57, 26.3% vs non-clustered: 
31/235, 13.2%; p = 0.024).
The levels of baseline median viral load were comparable between patients infected with HIV-1 strains of 
clustered and non-clustered sequences. The median CD4+ T-cell count at diagnosis was significantly higher 
among patients from whom clustered HIV-1 sequences were obtained than among persons with non-clustered 
viral sequences (clustered: 502 vs non-clustered: 399; p = 0.041), and accordingly, the proportion of patients with 
Characteristics
All patients
Patients with HIV-1 infection
P
Recent Long-term
n (%) n (%) n (%)
Number enrolled 292 (100.0) 46 (15.8) 246 (84.2)
Sexa
  Female 25 (8.6) 3 (6.5) 22 (9.0) 0.777b
  Male 265 (91.4) 43 (93.5) 222 (91.0)
Age at HIV-1 diagnosisa
Median (interquartile range) 29 (25–35) 29 (24–33) 30 (25–35) 0.171c
  <30 151 (52.1) 28 (60.9) 123 (50.4) 0.203b
  ≥30 139 (47.9) 18 (39.1) 121 (49.6)
City of HIV-1 diagnosis 0.027d
  Chorzów 130 (44.5) 17 (37.0) 113 (45.9) 0.332e
  Kraków 41 (14.0) 3 (6.5) 38 (15.5) 0.163e
  Łódź 39 (13.4) 5 (10.9) 34 (13.8) 0.813e
  Wrocław 82 (28.1) 21 (45.7) 61 (24.8) 0.007e
Self-reported HIV-1 transmission route 0.728d
  Sex between men (MSM) 199 (68.2) 35 (76.1) 164 (66.7) 0.232e
  Sex between women and men (HET) 48 (16.4) 5 (10.9) 43 (17.5) 0.385e
  Sex between men or women and men 
(MSM/HET) 13 (4.5) 2 (4.3) 11 (4.5) 1.000
e
  Injecting drug use (IDU)& 20 (6.8) 3 (6.5) 17 (6.9) 1.000e
  Other/Unknown 12 (4.1) 1 (2.2) 11 (4.5) 0.699e
CCR5 Δ32 genotype status 0.039d
  wt/wt 228 (78.1) 38 (82.6) 190 (77.2) 0.560e
  wt/Δ32 63 (21.6) 7 (15.2) 56 (22.8) 0.330e
  Δ32/Δ32 1 (0.3) 1 (2.2) — 0.158e
HIV-1 viral load at diagnosis, median log 
copies/ml (interquartile range) 4.47 (3.86–5.06) 4.19 (3.32–4.81) 4.51 (3.93–5.08) 0.045
c
CD4+ T-cell count at diagnosis, median 
cells/µl (interquartile range)
411 (292.5–579) 
(n = 272)
564 (374–722) 
(n = 43)
396 (280–545) 
(n = 229) 0.002
c
No. of patients with CD4+ T-cell count 
at diagnosis 0.014
d
  <200/µl 38 (14.0) 4 (9.3) 34 (14.8) 0.473e
  200–349/µl 63 (23.2) 5 (11.6) 58 (25.3) 0.051e
  350–499/µl 66 (24.3) 8 (18.6) 58 (25.3) 0.439e
  >500/µl 105 (38.6) 26 (60.5) 79 (34.5) 0.002e
Table 1. Characteristics of the study participants diagnosed in the years 2008–2014 with HIV-1 env sequences 
available. afor 2 individuals with long-term HIV-1 infection data on sex and age were not available, btwo-tailed 
Fisher’s exact test, cMann-Whitney U test, dPearson’s Chi-square test, etwo-tailed Fisher’s exact test comparing 
the specified category vs all other categories, &includes persons who reported injecting drug use together with 
heterosexual intercourses (n = 11) or with sex between men (n = 1).
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CD4+ T-cell counts of <200/µl was significantly lower among those harbouring HIV-1 with clustered sequences, 
while the proportion of patients with >500 CD4+ T-cell counts among them was significantly higher (Table 4).
To give a more detailed description of the 57 patients harbouring HIV-1 with clustered sequences and puta-
tively engaged in transmission events, the numbers of clusters gathering HIV-1 sequences from patients of the 
same characteristics (sex, age group, city of diagnosis, transmission route, non-R5 strain infection, HIV-1 infec-
tion status), as well as the numbers of sequences in such clusters, were calculated (Table 4). Since the major-
ity of clustered HIV-1 sequences were obtained from men, also the majority of clusters contained exclusively 
sequences obtained from men (25 clusters with 53 sequences), and only a single cluster contained one sequence 
from a woman and another from a man. Nine clusters included 18 HIV-1 sequences from persons under 30 
years old only, 6 clusters contained 13 HIV-1 sequences from persons ≥30 years old only, and 11 clusters gath-
ered 24 sequences from patients of <30 and ≥30 together. One cluster contained 2 sequences from persons for 
whom the information on sex and age was unavailable. The majority of clusters included sequences obtained from 
patients diagnosed with HIV-1 in the same location (23 clusters with 49 sequences). In the 4 remaining clusters, 
sequences obtained from patients recruited in different centres were grouped; within each of these 4 clusters there 
was 1 sequences from patient diagnosed in Chorzów combined either with sequence from patient diagnosed in 
Wrocław (3 clusters) or in Kraków (1 cluster) (Table 4, Fig. 2a).
The majority of clusters included sequences from persons who declared the same route of HIV-1 transmission, 
namely 17 clusters contained 36 sequences obtained exclusively from MSM, and 1 cluster gathered 2 sequences 
from persons with unknown transmission route (Table 4, Figs 1 and 2b). Among the remaining 9 mixed clusters, 
all but one contained at least one sequence from an MSM or MSM who also reported sex with women. Three 
mixed clusters included sequences from injecting drug users (IDUs), but none of these 3 sequences came from a 
person with RHI.
Most of clustered HIV-1 sequences obtained from patients with LTHI (27/42) were grouped within 13 clusters 
gathering only the sequences from patients with LTHI (Table 4, Figs 1 and 2c). The next 13 clusters contained 
sequences from both, persons with LTHI (15 sequences) and patients with RHI (13 sequences). There was only 
one cluster with 2 sequences from patients with RHI only.
To infer about possible transmission events from patients with recent HIV-1 infection we examined the sam-
ple collection dates for persons with viral sequences gathered in a single transmission cluster. These dates were 
checked for all 14 clusters containing 15 sequences obtained from patients with RHI. Onward transmission dur-
ing the recency period could not be the case for any of the 2 patients with RHI, whose viral sequences were 
grouped in a single cluster, since one patient was recruited to the study over 4 years earlier than the second one, 
and therefore could be engaged in transmission only during long-standing HIV-1 infection. For 10 out of 13 
mixed clusters, i.e. containing sequences from persons with RHI and LTHI, the date of sample collection for a 
patient with RHI was less than 6 months earlier than the sampling date for any patient with LTHI involved in the 
same cluster, thus we were not able to unambiguously demonstrate that these patients with recent HIV-1 infection 
were engaged in forward transmission.
As many as 23 clusters contained sequences of HIV-1 strains of the same tropism, among them there were 
17 clusters with 36 sequences of R5 strains, and 6 clusters with 12 sequences of non-R5 variants. The remaining 
9 clustered sequences were included within 4 mixed clusters, with sequences of R5 and non-R5 strains gathered 
simultaneously in each cluster (Table 4, Figs 1 and 2). Non-R5 strains were identified among 11 out of 46 patients 
Characteristics
HIV-1 from all 
patients
HIV-1 from patients with infection
P
Recent Long-term
n (%) n (%) n (%)
Number enrolled 292 (100.0) 46 (15.8) 246 (84.2)
HIV-1 subtype (based on gp120 sequences) 0.176a
  B 279 (95.6) 43 (93.5) 236 (95.9) 0.438b
  A6 8 (2.7) 1 (2.2) 7 (2.9) 1.000b
  CRF50_A1D 3 (1.0) 1 (2.2) 2 (0.8) 0.403b
  CRF02_AG 1 (0.3) — 1 (0.4) 1.000b
  F1 1 (0.3) 1 (2.2) — 0.158b
Non-R5 strains according to:
  Geno2pheno 10% FPR (subtype B)  + PhenoSeq (non-B subtypes) 68 (23.3) 11 (23.9) 57 (23.2) 1.000c
    Geno2pheno
    5.75% FPR 28 (9.6) 4 (8.7) 24 (9.8) 1.000c
    10% FPR 68 (23.3) 11 (23.9) 57 (23.2) 1.000c
    15% FPR 102 (34.9) 18 (39.1) 84 (34.2) 0.506c
    20% FPR 133 (45.5) 23 (50.0) 110 (44.7) 0.523c
Geno2pheno %FPR - median (interquartile range) 23.5 (10.5–49.8) 19.5 (10.5–55.7) 23.7 (10.5–49) 0.578d
Frequency of ambiguous nucleotides in env sequences, % - 
median (interquartile range) 0 (0–0.28) 0 (0–0) 0.14 (0–0.41) <0.001
d
Table 2. Virus characteristics based on gp120 sequences obtained from the study participants in the years 
2008–2014. aPearson’s Chi-square test, btwo-tailed Fisher’s exact test comparing the specified category vs all 
other categories, ctwo-tailed Fisher’s exact test, dMann-Whitney U test.
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with RHI, which may suggest acquisition of non-R5 variants for these patients. Among these 11 patients there 
were 5 with viral sequences grouped within 5 separate transmission clusters, and 6 with non-clustered sequences. 
More detailed characteristic of all patients with putative acquired non-R5 strains infection is presented in Table 5. 
Briefly, patients with possible acquired non-R5 infection were MSM with HIV-1 subtype B, most of them (7/11) 
were diagnosed in Chorzów. CCR5 genotypes wt/Δ32 and Δ32/Δ32 were identified in 3 of 11 patients (27.3%) 
with putative acquired non-R5 strains infection, and were not significantly more frequent than among patients 
with RHI harbouring R5 strains (5/35, 14.3%; p = 0.374). Among 5 clustered sequences obtained from patients 
with recent HIV-1 infection and non-R5 strains, there were 4 that grouped with non-R5 strains, further support-
ing potential acquisition of non-R5 strains for 4 out of 46 patients with RHI (8.7%) (Table 5).
Time trends. The proportion of patients diagnosed during recent HIV-1 infection has increased significantly 
from 9.9% (7/71) in 2008 to 23.6% (13/55) in 2013 and 25% (1/4) in 2014 with an average annual difference 
Patient and virus characteristics
All patients with HIV-1 
strains
P
Patients with recent 
infection (n = 46) with HIV-
1 strains
P
Non-R5 
(%) N = 68 
(23.3%)
R5 (%) 
N = 224 
(76.7%)
Non-R5 
(%) N = 11 
(23.9%)
R5 (%) N = 35 
(76.1%)
Sexa
  Female 5 (7.4) 20 (9.0) 0.808b 0 3 (8.6) 0.569b
  Male 63 (92.7) 202 (91.0) 11 (100.0) 32 (91.4)
Age at HIV-1 diagnosisa
  Median (interquartile range) 29 (26–34) 29 (25–35) 0.981c 28 (22–32) 29 (25–34) 0.699c
  <30 37 (54.4) 114 (51.4) 0.679b 7 (63.6) 21 (60.0) 1.000b
  ≥30 31 (45.6) 108 (48.6) 4 (36.4) 14 (40.0)
City of HIV-1 diagnosis 0.408d 0.184d
  Chorzów 35 (51.5) 95 (42.4) 0.211e 7 (63.6) 10 (28.6) 0.070e
  Kraków 9 (13.2) 32 (14.3) 1.000e 0 3 (8.6) 0.569e
  Łódź 10 (14.7) 29 (12.9) 0.688e 1 (9.1) 4 (11.4) 1.000e
  Wrocław 14 (20.6) 68 (30.4) 0.126e 3 (27.3) 18 (51.4) 0.188e
Self-reported HIV-1 transmission route 0.342d 0.337d
  Sex between men (MSM) 53 (77.9) 146 (65.2) 0.054e 11 (100.0) 24 (68.6) 0.044e
  Sex between women and men (HET) 8 (11.8) 40 (17.9) 0.268e 0 5 (14.3) 0.317e
  Sex between men or women and men (MSM/HET) 2 (2.9) 11 (4.9) 0.739e 0 2 (5.7) 1.000e
  Injecting drug use (IDU) 4 (5.9) 16 (7.1) 1.000e 0 3 (8.6) 0.569e
  Other/Unknown 1 (1.5) 11 (4.9) 0.307e 0 1 (2.9) 1.000e
CCR5 Δ32 genotype status 0.135d 0.179d
  wt/wt 50 (73.5) 178 (79.5) 0.317e 8 (72.7) 30 (85.7) 0.374e
  wt/Δ32 17 (25.0) 46 (20.5) 0.501e 2 (18.2) 5 (14.3) 1.000e
  Δ32/Δ32 1 (1.5) — 0.233e 1 (9.1) 0 0.239e
HIV-1 viral load at diagnosis, median log copies/ml 
(interquartile range)
4.48 
(3.74–5.01)
4.47 
(3.87–5.07) 0.526
c 4.39 
(3.74–4.80)
4.17 
(3.26–4.82) 0.988
c
CD4+ T-cell count at diagnosis, median cells/µl 
(interquartile range)
349.5 
(202–604) 
(n = 66)
432.5 
(316–571) 
(n = 206)
0.066c 651 (279–766)
550.5 
(385.5–662.5) 
(n = 32)
0.513c
No. of patients with CD4+ T-cell count at diagnosis 0.027d 0.731d
  <200/µl 16 (24.2) 22 (10.7) 0.008e 1 (9.1) 3 (9.4) 1.000e
  200–349/µl 17 (25.8) 46 (22.3) 0.616e 2 (18.2) 3 (9.4) 0.589e
  350–499/µl 12 (18.2) 54 (26.2) 0.248e 1 (9.1) 7 (21.9) 0.656e
  >500/µl 21 (31.8) 84 (40.8) 0.245e 7 (63.6) 19 (59.4) 1.000e
HIV-1 subtype 0.858d 0.799d
  B 66 (97.1) 213 (95.1) 0.739b 11 (100.0) 32 (91.4) 0.569b
  Non-B 2 (2.9) 11 (4.9) 0 3 (8.6)
No. of ambiguous nucleotides in V3 coding region 
(mean ± standard deviation) 0.5 ± 1.3 0.4 ± 1.0 0.793
c 0 0.03 ± 0.2 0.610c
No. of ambiguous amino acids in V3 
(mean ± standard deviation) 0.4 ± 1.1 0.3 ± 0.9 0.716
c 0 0 —
Table 3. Comparison of patients harbouring non-R5 and R5 strains predicted by V3 analysis with geno2pheno 
10% FPR (for subtype B) and PhenoSeq (for non-B subtypes) algorithms. afor 2 individuals with R5 strain 
infection data on sex and age were not available, btwo-tailed Fisher’s exact test, cMann-Whitney U test, 
dPearson’s Chi-square test, etwo-tailed Fisher’s exact test comparing the specified category vs all other categories.
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of +3.15% per year (OR: 1.26, 95% CI: 1.07–1.48, p = 0.005) (Table 6). Consistently, there were significantly 
increasing mean CD4+ T-cell counts from 460 ± 249 in 2008 to 550 ± 354 in 2013 (slope =+22.1/year, p = 0.008). 
Significantly increasing trend in the CD4+ T-cell counts was not visible, when the analysis was restricted to 
Characteristics
Patients with HIV-1 
sequences
P
Clustered sequences (n = 57) and clusters (n = 27) 
with
P
clustered 
(%)*
non-
clustered 
(%) the same characteristics
different characteristics 
(mixed)
N = 57 
(19.5%)
N = 235 
(80.5%)
no. of 
sequences, %
no. of 
clusters
no. of 
sequences, %
no. of 
clusters
Sexa
  Female 1 (1.8) 24 (10.2) 0.058b 0 0 1 (1.8) 1 0.036b
  Male 54 (98.2) 211 (89.8) 53 (96.4) 25 1 (1.8)
Age at HIV-1 diagnosisa
  Median (interquartile range) 29 (23–35) 29 (25–35) 0.414c
  <30 30 (54.5) 121 (51.5) 0.765b 18 (32.7) 9 12 (21.8) 11 0.595b
  ≥30 25 (45.5) 114 (48.5) 13 (23.6) 6 12 (21.8)
City of HIV-1 diagnosis 0.907d 0.728d
  Chorzów 27 (47.4) 103 (43.8) 0.658e 23 (40.4) 11 4 (7.0) 4 1.000e
  Kraków 8 (14.0) 33 (14.0) 1.000e 7 (12.3) 3 1 (1.8) 1.000e
  Łódź 6 (10.5) 33 (14.0) 0.664e 6 (10.5) 3 0 0.580e
  Wrocław 16 (28.1) 66 (28.1) 1.000e 13 (22.8) 6 3 (5.3) 0.674e
Self-reported HIV-1 transmission 
route <0.001
d <0.001d
  Sex between men (MSM) 44 (77.2) 155 (66.0) 0.115e 36 (63.2) 17 8 (14.0) 9 <0.001e
  Sex between women and men (HET) 0 48 (20.4) <0.001e — — — —
  Sex between men or women and men 
(MSM/HET) 4 (7.0) 9 (3.8) 0.290
e 0 0 4 (7.0) 0.010e
  Injecting drug use (IDU) 3 (5.3) 17 (7.2) 0.774e 0 0 3 (5.3) 0.033e
  Other/Unknown 6 (10.5) 6 (2.6) 0.015e 2 (3.5) 1 4 (7.0) 0.088e
CCR5 Δ32 genotype status 0.879d
  wt/wt 45 (78.9) 183 (77.9) 1.000e
  wt/Δ32 12 (21.1) 51 (21.7) 1.000e
  Δ32/Δ32 0 1 (0.4) 1.000e
HIV-1 viral load at diagnosis, median 
log copies/ml (interquartile range)
4.26 
(3.67–4.95)
4.51 
(3.89–5.07) 0.118
c
CD4+ T-cell count at diagnosis, 
median cells/µl (interquartile range)
502 (323.5–
605.5) 
(n = 52)
399 
(281.5–568) 
(n = 220)
0.041c
No. of patients with CD4+ T-cell 
count at diagnosis 0.014
d
  <200/µl 2 (3.8) 36 (16.4) 0.024e
  200–349/µl 15 (28.8) 48 (21.8) 0.278e
  350–499/µl 8 (15.4) 58 (26.4) 0.108e
  >500/µl 27 (51.9) 78 (35.5) 0.039e
HIV-1 subtype 0.849d
  B 55 (96.5) 224 (95.3) 1.000b
  Non-B 2 (3.5) 11 (4.7)
HIV-1 tropismf
  Non-R5 strains 16 (28.1) 52 (22.1) 0.383b 12 (21.1) 6 4 (7.0) 4 0.250b
  R5 strains 41 (71.9) 183 (77.9) 36 (63.2) 17 5 (8.8)
HIV-1 infection status
  Recent 15 (26.3) 31 (13.2) 0.024b 2 (3.5) 1 13 (22.8) 13 <0.001b
  Long-term 42 (73.7) 204 (86.8) 27 (47.4) 13 15 (26.3)
Table 4. Comparison of patients with clustered and non-clustered HIV-1 env sequences and characteristics 
of clusters identified among 292 HIV-1 sequences. *clusters were selected based on aLRT value in ML method 
>0.9, maximum within cluster pairwise genetic distance threshold of 3%, and posterior probability in a 
Bayesian inference = 1, afor 2 individuals with clustered HIV-sequences data on sex and age were not available, 
btwo-tailed Fisher’s exact test, cMann-Whitney U test, dPearson’s Chi-square test, etwo-tailed Fisher’s exact 
test comparing the specified category vs all other categories, faccording to geno2pheno 10% FPR (subtype 
B) + PhenoSeq (non-B subtypes).
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patients with RHI (p = 0.286), but was true for the group of patients with LTHI (slope =+18.0/year, p = 0.047). 
Analysis of the viral load revealed no significant time trends, neither for all patients nor for patients with RHI or 
LTHI, separately.
In line with the decreasing proportion of women among HIV-1 infections (from 11.3%, 8/71 in 2008 to 0% in 
2013 and 2014; average annual difference = −2.38%/year, OR: 0.68, 95% CI: 0.52–0.91, p = 0.003), the proportion 
of MSM has increased significantly from 53.5% (38/71) in 2008 to 85.5% (47/55) in 2013 and 75% (3/4) in 2014 
(average annual difference =  + 6.80%/year, OR: 1.43, 95% CI: 1.23–1.66, p < 0.001), and the percent of patients 
who reported heterosexual intercourses as a transmission route significantly decreased in this time period from 
22.5% (16/71) to 3.6% (2/55) and 0% in 2014 (average annual difference = −5.10%/year, OR: 0.61, 95% CI: 0.49–
0.77, p < 0.001), while the proportion of IDUs was stable (p = 0.340). Similar temporal trends for the mode of 
HIV-1 transmission were visible within the group of patients with LTHI, while the proportions of persons with 
the three transmission routes did not change significantly among patients with RHI (Table 6).
The proportion of non-R5 strains was stable over time with a slight decrease over the studied period (average 
annual difference = −1.52%/year, p = 0.234), and geno2pheno FPR values were also stable over time (p = 0.404). 
Similarly, there was a stable proportion of clustered HIV-1 sequences (p = 0.634), and the percent of infections 
with non-B subtypes over time (p = 0.445). The age at diagnosis was also stable throughout the examined time 
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Figure 1. MCMC phylogenetic tree of env sequences obtained from 292 patients diagnosed in Poland in 
the years 2008–2014. Transmission clusters identified with the maximum likelihood aLRT value of >90%, 
maximum intracluster pairwise genetic distance <3%, and posterior probability of 1 in Bayesian inference are 
highlighted. Clusters highlighted in green contain sequences obtained from patients with long-term and recent 
HIV-1 infection. Clusters highlighted in grey and light blue contain sequences obtained from patients with 
long-term HIV-1 infection only and recent HIV-1 infection only, respectively. Squares indicate the presence of 
non-R5 strains. Self-reported transmission routes for patients with clustered HIV-1 sequences are specified with 
MSM (for sex between men), MSM/HET (for sex between men or women and men), IDU (for injecting drug 
use), O/Unk (for other/unknown). Majority of sequences represented subtype B, thus only non-B subtypes are 
indicated.
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range (p = 0.108). The same stable trends were observed in the separate analyses restricted to the patients with 
RHI and LTHI, with the exception of a tendency to the less frequent clustered transmission through years among 
patients with RHI (p = 0.074) (Table 6).
Discussion
In the studied group of 292 patients with HIV-1 infection diagnosed in the years 2008–2014 in four centers for 
HIV Diagnostics and Therapy for AIDS located in southern and central Poland (Chorzów, Kraków, Łódź, and 
Wrocław) recent HIV-1 infections accounted for 15.8% of all newly diagnosed infections. This is a much smaller 
proportion of recent infections than observed in Poland in 2006 with the BED assay (44%)27. Although the latter 
may have been overestimated due to the substantial false recent rate of the BED test, it also coincides with sig-
nificant upsurge of infections among MSM, which occurred in the mid-200028. Thus, the smaller, but gradually 
increasing, percent of recent infections observed in the current study likely represents a real feature of the epi-
demic. In the current study recent HIV-1 infection status was detected with quantitative limiting antigen avidity 
enzyme immunoassay (LAg-Avidity EIA), which provides the false recent rate as low as 1.3% (0.3–3.2)29. The 
accuracy of RHI assessment by the LAg-Avidity EIA seems to be supported by the significantly lower frequency 
of ambiguous nucleotides in env sequences obtained from individuals with RHI than in sequences from patients 
with LTHI, as the proportion of ambiguous nucleotides is known to increase with the stage of infection30.
Figure 2. HIV-1 transmission clusters inferred from the analysis of env sequences obtained from 292 study 
participants diagnosed in the years 2008–2014. Clusters were identified with the maximum likelihood aLRT 
value of >90%, maximum intracluster pairwise genetic distance <3%, and posterior probability of 1 in Bayesian 
inference. Viral tropism is indicated with shapes: squares and circles represent sequences of non-R5 and R5 
strains, respectively. For all patients with clustering viral sequences shapes are colored according to: city of 
HIV-1 diagnosis (a), self-reported transmission route (MSM - sex between men, MSM/HET - sex between men 
or women and men, IDU - injecting drug use, O/Unk - other/unknown) (b), and duration of HIV-1 infection 
(c).
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The overall frequency of non-B subtypes in the examined group was 4.5% (13/292), and was comparable 
for patients with recent and long-term HIV-1 infection. Nevertheless, this value was considerably lower than 
the frequency of non-B clades determined in other Polish study covering similar time period (112/946; 11.8%; 
p < 0.001)31. The generally low frequency of non-B HIV-1 variants observed in our study may be explained by low 
frequency of non-B subtypes among samples obtained from patients diagnosed in Upper Silesia region (Chorzów, 
2/130; 1.5%), which constituted the most prevalent group in our research, and were not included in the previous 
Cluster Patient Sex
Age at HIV-1 
diagnosis
City of HIV-
1 diagnosis
Self-reported 
HIV-1 
transmission 
route
HIV-1 
infection 
status
Month and year of 
sample collection
CCR5 Δ32 
genotype 
status
HIV-1 
subtype
Viral tropism 
according to 
geno2pheno 
(FPR%)
Yes 2* 6938 MNS Male 21 Chorzów MSM Recent May 2009 wt/Δ32 B Non-R5 (6.9)
7051 KKSa Male 29 Chorzów MSM Long-term June 2009 wt/wt B Non-R5 (6.7)
Yes 5* 6903 TRS Male 26 Chorzów MSM Recent April 2009 wt/wt B Non-R5 (1.7)
40 KOKa Male 33 Kraków MSM Long-term January 2010 wt/wt B Non-R5 (1.7)
Yes 7* 17 RKD Male 32 Wrocław MSM Recent September 2012 wt/wt B Non-R5 (9.6)
19 MSDa Male 26 Wrocław MSM Long-term September 2012 wt/wt B Non-R5 (9.6)
Yes 8* 7987 LSS Male 21 Chorzów MSM Recent October 2010 wt/wt B Non-R5 (7.4)
7019 KGSa Male 23 Chorzów MSM Long-term September 2009 wt/wt B Non-R5 (7.4)
Yes 9* 53 SCD Male 29 Wrocław MSM Recent September 2013 wt/Δ32 B Non-R5 (6.9)
20 KPDa Male 37 Wrocław MSM Recent April 2009 wt/wt B R5 (46.2)
No* 610 LJE Male 37 Łódź MSM Recent June 2008 wt/wt B Non-R5 (6.0)
No* 6571 JJ Male 44 Chorzów MSM Recent September 2008 wt/wt B Non-R5 (3.9)
No* 7595 PSS Male 30 Chorzów MSM Recent June 2010 wt/wt B Non-R5 (7.1)
No* 8031 RFS Male 28 Chorzów MSM Recent November 2010 wt/wt B Non-R5 (8.2)
No* 10055 DCS Male 22 Chorzów MSM Recent March 2013 Δ32/Δ32 B Non-R5 (1.7)
No* 57 SSD Male 24 Wrocław MSM Recent February 2014 wt/wt B Non-R5 (0.1)
Table 5. Possible acquired non-R5 strains infections among patients with clustered and non-clustered HIV-1 
sequences. *data of patients with possibly acquired non-R5 strain infection, adata of the partner involved in the 
same cluster (possible source of infection), MSM – sex between men, FPR – false positive rate.
Patient and virus 
characteristicsa
All patients Patients with recent HIV-1 infection Patients with long-term HIV-1 infection
OR (95%CI) P
average 
annual 
difference OR (95%CI) P
average 
annual 
difference OR (95%CI) P
average 
annual 
difference
Recent HIV-1 infection 1.26 (1.07–1.48) 0.005 +3.15%
Female 0.68 (0.52–0.91) 0.003 −2.38% ND ND ND 0.75 (0.56–1.00) 0.033 −1.96%
Self-reported HIV-1 transmission route
  MSM 1.43 (1.23–1.66) <0.001 +6.80% 1.23 (0.86–1.75) 0.245 +3.75% 1.46 (1.23–1.73) <0.001 +7.30%
  HET 0.61 (0.49–0.77) <0.001 −5.10% 0.72 (0.43–1.21) 0.191 −3.05% 0.60 (0.46–0.78) <0.001 −5.43%
  IDU 0.89 (0.69–1.14) 0.340 −0.72% 1.14 (0.61–2.14) 0.667 +0.79% 0.84 (0.62–1.12) 0.213 −1.04%
Non-R5 strainsb 0.92 (0.79–1.06) 0.234 −1.52% 0.89 (0.63–1.27) 0.528 −2.04% 0.92 (0.78-1.08) 0.290 −1.50%
Clustered HIV-1 
transmission (3% genetic 
distance threshold)
1.04 (0.89-1.21) 0.634 +0.58% 0.75 (0.53-1.04) 0.074 −6.30% 1.10 (0.93–1.31) 0.283 +1.39%
HIV-1 non-B subtype 1.12 (0.84–1.48) 0.445 +0.49% 1.14 (0.61–2.14) 0.667 +0.79% 1.09 (0.79–1.51) 0.610 +0.35%
slope/year (95%CI) P slope/year (95%CI) P slope/year (95%CI) P
Age at HIV-1 diagnosis, 
years −0.41 (−0.91–0.09) 0.108 −0.50 (−1.58–0.58) 0.357 −0.33 (−0.90–0.25) 0.263
HIV-1 viral load at 
diagnosis, log copies/ml −4.03 (−4.59–4.24) 0.455 +4.22 (−4.63–4.88) 0.572 −4.20 (−4.68–4.22) 0.335
CD4+ T-cell count at 
diagnosis, cells/μl +22.1 (5.9–38.3) 0.008 +23.2 (−20.0–66.6) 0.286 +18.0 (0.2–35.8) 0.047
Geno2pheno %FPR +0.64 (−0.87–2.14) 0.404 +0.52 (−3.20–4.24) 0.780 +0.77 (−0.91–2.46) 0.368
Table 6. The logistic and linear regression analyses of time trends in selected parameters for patients with 
recent and long-term HIV-1 infection – years 2008–2014. ain the first column outcome variables are specified, 
the year of HIV-1 diagnosis was a single predictor in the logistic and linear regression analyses, baccording to 
geno2pheno 10% FPR (subtype B) + PhenoSeq (non-B subtypes), ND – not determined, MSM – sex between 
men, HET – sex between women and men, IDU – injecting drug use, FPR – false positive rate.
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study. This finding supports the notion that the prevalence of non-B HIV-1 subtypes may differ by geographic 
region. Additionally, HIV-1 infections with sub-subtype A6 and CRF50_A1D which were previously reported to 
spread in former Soviet Union area and Western European countries, respectively32,33, were detected in Poland for 
the first time. Similarly to the previous study31, the proportion of non-B variants in our study was stable through-
out the study period.
Admittedly, patients with HIV-1 diagnosis during long-term infection predominated in our study. However, 
we found both, a significant increase of the proportion of recent infections and an increase in CD4+ T-cell count 
among the new HIV diagnoses over the study period, from 2008 to 2014. These data suggest that during the study 
period the average time from infection to HIV diagnosis decreased, although this decrease was not spectacular 
and should be presumably measured in weeks or months rather than in years. Indeed, such a decline in the esti-
mated mean interval of time-to-HIV-diagnosis from 4.0 in 2001 to 3.2 years in 2010 was previously reported for 
MSM in United Kingdom34, and a gradual decrease of time from infection to diagnosis was observed between 
2012 and 2016 across the European Union35. It is also in line with the previously described increasing testing 
rates36, and higher rates of HIV-1 testing associated with the same-sex sexual exposure37.
The overall distribution of the transmission routes reported by patients with RHI and LTHI was comparable. 
However, there was a significant annual decrease in the proportion of women and individuals infected through 
heterosexual contact, coupled with an increase in proportion of MSM. These temporal trends for the HIV-1 
transmission route were observed within the whole studied group and among patients with LTHI and RHI sep-
arately, only in the latter group not reaching the level of significance. Hence, these data may confirm increase in 
the frequency of MSM testing for HIV-1 infection, and indicate that the epidemic among MSM in Poland was on 
the rise, while the increasing testing rates were still not sufficient to achieve an HIV diagnosis within the first 6 
months after infection in the majority of cases.
In the analysis of phylogenetic clusters, sequences from 15 (32.6%) out of 46 patients with RHI were included 
in 14 clusters. Similarly to other reports38,39, sequences from individuals with RHI were notably more frequent 
within the clusters than outside the clusters (26.3% vs 13.2%). This higher frequency may be explained by the 
fact that the samples obtained in early infection experience minimal genetic divergence and are more likely to 
cluster with the putative donor sequence24. Besides, the majority of clustering sequences obtained from patients 
with RHI (13/15) were grouped with the sequences derived from patients with LTHI. Considering that in most 
of these mixed clusters the date of sample collection for a patient with RHI was less than 6 months earlier than 
the sampling date for a patient with LTHI or the sample collection dates were the same for both patients, it may 
suggest that the patients with long-standing infection were presumably responsible for the virus propagation, 
with most of them likely transmitting the virus before being HIV-1-diagnosed, and thus being not aware of their 
HIV-1 status. Although such an assumption could be confirmed by the medical interview data only in the case of 
one pair of patients with RHI and LTHI, it is in line with the results of the country-wide survey performed among 
MSM in the Netherlands revealing that over 70% of transmission events in the years 1996–2010 originated from 
undiagnosed individuals40. On the other hand, the lack of clustering for 67.4% (31/46) of sequences from patients 
with RHI may indicate that a considerable proportion of HIV-1 infections could be transmitted by undiagnosed 
(or not linked to care) individuals. However, due to the relatively low sample size in our study, also individuals 
that were not sampled should be considered as a potential source of HIV-1 infection for patients with RHI.
The frequency of clustered HIV-1 sequences identified in our study (57/292, 19.5%) was within the range of 
the frequencies observed in other European and North American HIV-1-positive groups38,41–45. Similarly to other 
European and North American cohorts38,41–46 the proportion of MSM (together with men who reported sex with 
either men or women as a transmission route) was significantly higher among patients with clustered sequences 
compared to non-clustered (clustered: 48/57, 84.2% vs non-clustered: 164/235, 69.8%; p = 0.031), showing that, 
like in other regions, the epidemic in southern and central Poland has been driven mainly by MSM. However, 
according to our data, unlike in most other studies38,41,43–46, patients with clustered HIV sequences were not sig-
nificantly younger than patients with viral sequences located outside the clusters.
According to our data, the proportion of all sequences clustering with other sequences was stable over time 
or tended to decrease during the study period among samples obtained from patients with RHI. This is opposite 
to what was observed in a prior study in Poland, where significantly increasing trends for clustered transmis-
sions were reported46. However, we only collected samples from four of 16 regions in Poland. In our sample 
4/27 clusters (14.8%) contained sequences from different regions. Such interregional clusters with highly related 
sequences coming from different regions were also found by other researchers in Poland46 and Germany44, and 
in comparison to our results the proportion of these clusters was shown to be higher (31/109, 28.4% and 32/184, 
17.4%, respectively). It is possible that due to increasing mixing, other patients with clustering sequences were 
diagnosed in other regions of Poland, and therefore were not captured, explaining the lower than expected level 
of interregional clusters in our study. In line with other studies44,46, sequences from MSM were the most common 
in the interregional clusters (7/8, 87.5%), confirming the role of MSM in bridging regional HIV epidemics.
The overall prevalence of non-R5 strains in our study was 23% as detected with geno2pheno 10% FPR for 
subtype B samples and PhenoSeq for non-B subtypes or geno2pheno 10% FPR for all samples, and was slightly 
lower than non-R5 prevalence determined in the former study (28%) with the geno2pheno 10% FPR, among 
newly diagnosed patients from northern Poland22. This small discrepancy could have resulted from the diverse 
approach to tropism prediction in both studies, namely single vs triplicate sequencing of V3 coding region in the 
current and the previous study, respectively. Triplicate genotypic V3 testing is able detect more non-R5 variant 
in comparison with analysis of single sequences. However, tropism predictions using V3 genotyping based on 
single or triplicate testing using geno2pheno with a FPR of 10% were shown to be comparable, and the high con-
cordance of tropism prediction among samples with single and triplicate amplification stands behind the use of 
single amplification in diagnostic practice47–51. Alternatively, the lower frequency of non-R5 viruses in our study 
may be explained by the local, within-country differences in the occurrence of CXCR4-using strains. This may 
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be supported by the observed stable prevalence of non-R5 strains during the study period among all patients 
with new HIV-1 diagnoses and among patients with recent and long-term HIV-1 infection separately, whereas 
in previous study performed in northern Poland an increasing trend for the frequency of the non-R5 strains was 
reported among patients with new diagnoses22. It is also noteworthy that the median value of geno2pheno FPR in 
our study was relatively low (23.5%; (10.5–49.8%)), since it was demonstrated that low baseline FPR determined 
by the geno2pheno tool can predict tropism switch from CCR5 to CXCR4, and patients with R5 viruses predicted 
at diagnosis with a geno2pheno FPR of less than 50% (or <40.6%) were more prone to switch coreceptor over 
time than patients with FPR values of >50% (or >40.6)17,52.
The presence of non-R5 strains among persons with RHI may suggest possible transmission of non-R5 strains. 
In the current study, the frequency of non-R5 strains was comparable between groups of patients with RHI (24%) 
and LTHI (23%). Such a relatively high frequency of CXCR4-using strains among patients with RHI was not com-
monly observed in other groups of patients with similar characteristics (recent or acute HIV-1 infection, subtype 
B predominance, mainly sexual mode of transmission), and similar method of tropism prediction (geno2pheno 
with 10% FPR). For instance, according to genotypic tropism testing performed on proviral DNA in Italy only 3% 
of patients with RHI were infected with X4 strains11, and in other studies the frequency of CXCR4-using strains 
among patients at early infection stages was under 20%5,12,15–17,53. The relatively high frequency of non-R5 strains 
determined in the current study for patients with RHI deserves attention because of the restricted number of 
patients eligible to therapy with CCR5 antagonist, maraviroc, as well as in the light of the established correla-
tion between infection with the CXCR4-using strains and faster disease progression15,54, or first-line treatment 
failure19.
Although in current and other studies5,15,53,55,56 there were no significant differences between patients with 
RHI harbouring non-R5 and R5 viruses with regard to the baseline CD4+ T-cell count and viral load, longitudinal 
observations indicated that the presence of CXCR4-utilizing strains at the beginning of infection was associated 
with faster disease progression characterised by accelerated CD4+ T-cell count decline below 350 cells/μl5,53. 
Besides, no significant differences in sex, age, CCR5 Δ32 genotype, and HIV-1 subtype between patients with 
possible transmission of non-R5 and R5 strains were found in our research, confirming the results obtained in 
other studies15,53,57.
In our study, non-R5 strains among patients with RHI were observed exclusively in MSM, while patients with 
all other routes of HIV-1 transmission were harbouring R5 viruses. In some surveys addressing the issue of puta-
tive transmission of X4 strains to the new hosts, the route of HIV-1 transmission was similar among patients with 
R5 and X4 variants15,53,55,58, whereas in others, X4 viruses were more frequently detected in IDUs than in patients 
infected by sexual contacts5,56. In our study the number of RHI attributed to the transmission routes other than 
sex between men was very small, thus our ability to study the differences by transmission route was limited. 
Nonetheless, our observations are consistent with prior research suggesting that proposed barriers protecting 
against X4 strains infection via blood and mucosal epithelium, and possibly selecting for R5 variants during 
transmission8 are similarly not perfect, and the spread of non-R5 and R5 strains may occur as a random process57.
Since detection of non-R5 strains among patients with RHI may reflect either the initial transmission of such 
strains or rapid evolution of X4 viruses from acquired R5 strains, to further address the issue of possible transmis-
sion of non-R5 strains to the new hosts among MSM, the analysis of transmission clusters identified by phyloge-
netic approach was performed. Among 11 patients with RHI and non-R5 strains, 5 had their HIV-1 sequences 
included within separate phylogenetic clusters indicating related transmission. Only in one of these 5 clusters 
HIV-1 sequences presented different tropism (non-R5 and R5). These clustered sequences were derived from 2 
patients with RHI, however, the patient with R5 strain infection entered the study over 4 years earlier than the 
patient harbouring non-R5 variant. Thus, either he was not the immediate donor to the second patient, or he was 
not under successful treatment during 4 years after diagnosis. If the latter is true, it is possible that at the time of 
HIV-1 transmission, non-R5 variants could have emerged in the putative donor patient, initially infected with R5 
virus, and could have been transmitted to a new host. Unfortunately, we cannot confirm this assumption, since 
we have neither an additional, later sample from the patient with R5 strain infection nor additional clinical infor-
mation. In the remaining 4 clusters the second patient involved in the same cluster (putative donor) was a person 
with LTHI, also harbouring non-R5 strains, which may indicate the acquisition of non-R5 viruses, and the prev-
alence of acquired non-R5 HIV-1 infection confirmed by the phylogenetic analysis can be settled at 8.7% (4/46). 
Studies in which the possibility of transmission of non-R5 strains was evaluated using phylogenetic clusters anal-
ysis are scarce, and give inconsistent results. Frange et al.58 failed to confirm the transmission of non-R5 strains 
in the group of patients with primary HIV-1 infection, as only 1 out of 27 non-R5 sequences was present within a 
transmission cluster, and grouped with the sequence of an R5 strain obtained from a patient who was infected 34 
months after infection of the presumed donor harbouring non-R5 virus. In turn, our data are congruent with the 
results presented by Chalmet et al.57. In their study transmission of non-R5 strains was suggested by the presence 
of non-R5 sequences within common phylogenetic clusters, and was confirmed by the identification of non-R5 
strains in both partners of well-recognised transmission pairs shortly after infection, supporting the hypothesis 
of random spread of strains presenting non-R5 or R5 tropism.
The major limitation of our study is a relatively small sample size, hence we received small cluster sizes (mostly 
pairs) and some important transmission links could be omitted. Although patients included in the analysis con-
stituted an estimated sample of 16% of all new diagnoses detected in the studied provinces during study period, 
and such a sample is expected to be representative of the examined area, the interpretation of the transmission 
clusters in such a case should be performed with the extreme caution. Especially, it should be considered that 
individuals who were not sampled can be either the intermediate hosts between patients with viral sequences 
gathered within the same cluster or the direct source of HIV-1 infection for them.
Another limitation of our study is linked to the years of samples collection, i.e. 2008–2014. While it is intrinsic 
to the similar types of studies that sampling considerably precedes the time of publication making the results 
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significant for the earlier time periods38,39,45,59, we have tried to extend the validity of our study by conducting the 
time trends analyses.
Moreover, unlike in most other studies where pol HIV-1 sequences were used, we have used env gene 
sequences to detect phylogenetic transmission clusters, which complicates direct comparisons between studies. 
However, it was recently found that env sequences, due to their higher variability, may be more suitable than the 
pol sequences for analysis of recent infections59.
Finally, tropism predictions in our study were performed solely with the genotypic methods. Although 
genotypic tropism testing is currently accepted as an alternative to the phenotypic testing47,60, and >80% con-
cordance between phenotypic assays and the geno2pheno method used for subtype B tropism assessment was 
reported51,61–65, it was shown that detection of CXCR4-using viruses by some genotypic assays may be inaccurate, 
especially for non-B subtypes61,66,67. Thus, to predict the tropism in non-B HIV-1 samples we used PhenoSeq, a 
tool with improved sensitivity and specificity for establishing the tropism of non-B subtypes68. Nevertheless, the 
discrepant results of the genotypic and phenotypic tropism assays were reported for patients with acute or recent 
infections5,13,14,16, indicating that our tropism predictions should be interpreted with caution.
In conclusion, we found relatively high prevalence of non-R5 strains among Polish patients with new HIV-1 
diagnoses (23%) and recent infections (24%), but we did not confirm the increasing trend for the frequency of 
non-R5 viruses among newly diagnosed individuals reported in a former Polish study. Transmission of non-R5 
viruses was confirmed by cluster analysis for 8.7% (4/46) patients with RHI. Non-R5 strain distribution and 
recent HIV-1 infection frequency, as well as the prevalence of non-B subtypes in Poland may differ by geographic 
region. Although viral sequences obtained from individuals with RHI were notably more frequent within the 
transmission clusters than outside them, the participation of these individuals in the forward HIV-1 transmission 
was not confirmed.
Methods
Study group and sample collection. The study was performed among 298 consecutive Polish patients 
who were recruited under the following inclusion criteria: (1) being newly diagnosed with HIV-1 infection, and 
having no clinical AIDS (indicator disease) at first testing; (2) presenting at 1 of 4 centers for HIV Diagnostics 
and Therapy for AIDS in Poland placed in Chorzów, Kraków, Łódź, and Wrocław, during the enrolment period, 
between March 2008 and February 2014; (3) having their blood sample collected at first presentation; and (4) pro-
viding written informed consent to participate in the study. During the recruitment procedure the data regarding 
sex, age, date and city of HIV-1 diagnosis, as well as self-reported transmission route were collected. Viral load 
and CD4+ T-lymphocyte at HIV-1 diagnosis were retrieved from patients’ medical records and were the first 
results obtained after HIV-1 diagnosis. Anticoagulated venous blood and plasma samples were collected at first 
clinical presentation and were stored at –80 °C until further laboratory procedures were performed.
All plasma samples were tested with the quantitative limiting antigen avidity enzyme immunoassay (SediaTM 
HIV-1 LAg-Avidity EIA, Sedia BioSciences Corporation, Portland, Oregon, USA) to differentiate recent from 
long-term HIV-1 infections. Assay was performed according to the manufacturer’s protocol69. As recommended, 
samples with normalized median optical density values (ODn) ≤ 1.5 in a triplicate confirmatory testing were 
considered to be obtained from persons with recent HIV-1 infection, which corresponds to a duration of HIV-1 
infection no longer than 130 days (95% CI: 118–142) since seroconversion70.
QIAamp DNA Blood Mini Kit (QIAGEN GmbH, Hilden, Germany) was used to extract genomic and proviral 
DNA from blood samples. The presence of 32 base-pair deletion in patients’ CCR5 gene (Δ32) was determined 
with the polymerase chain reaction (PCR) as described previously10,71.
Amplification and sequencing of HIV-1 env gene. Amplification of env gene fragments coding for 
gp120 region was performed with nested-PCR in 298 samples of genomic and proviral DNA obtained from 47 
patients with recent HIV-1 infection (RHI), and 251 persons with long-term infection (LTHI). In the first step of 
the nested-PCR, fragment spanning nucleotides 6201–9089 was amplified using E00-F and E01-R as outer prim-
ers72, with the following amplification conditions: an initial denaturation at 94 °C/7 minutes, followed by 40 cycles 
of 94 °C/40 seconds, 51 °C/40 seconds, and 72 °C/3 minutes, with the final extension at 72 °C/7 minutes, in a final 
volume of 50 μl. In the next step, inner primers ED5-F and E125-R were used to obtain 782 base pairs fragment 
of gp120 spanning nucleotides 6557-733872,73. Amplification conditions for inner primer pairs were as follows: 
94 °C/5 minutes, followed by 35 cycles of 94 °C/35 seconds, 55 °C/35 seconds, and 72 °C/90 seconds, with the final 
extension at 72 °C/5 minutes, in a final volume of 50 μl.
Purified nested-PCR products were subjected to the population-based sequencing with the ABI Prism Big 
Dye Terminator v3.1 cycle sequencing kit (Applied Biosystems, Foster City, CA, USA) with the primers used in 
the inner step of nested-PCR. For each sample, the sequences of both strands were determined separately using 
96-capillary 3730xl DNA Analyzer (Applied Biosystems, USA). The obtained sequences were manually checked 
and trimmed to remove primers, resulting in fragments spanning nucleotides from 6583 to 7314 corresponding 
to codons 121–363 of gp120, covering the complete coding sequence for V1, V2, C2 and V3 regions. Nucleotides 
were considered ambiguous, when the next highest peak in the electropherogram exceeded 25% of the main peak. 
All nucleotide positions in the manuscript are presented according to the numbering positions of HIV-1 HXB2 
(GenBank accession number: K03455). Amplification and sequencing was successful for 292 specimens, includ-
ing 46 originated from patients with RHI.
Analysis of HIV-1 env sequences and coreceptor usage prediction. All sequences were analysed 
for the presence of hypermutations using HYPERMUT software v2.074. HIV-1 subtypes were initially deter-
mined with REGA HIV-1 Subtyping Tool 3.0 (http://dbpartners.stanford.edu:8080/RegaSubtyping/stanford-hiv/
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typingtool), and afterward with NCBI Genotyping Tool using HIV-1 reference set from 2009 (https://www.ncbi.
nlm.nih.gov/projects/genotyping/formpage.cgi). The NCBI Genotyping Tool analyses were performed espe-
cially to check sequences determined as non-B or not assigned to any subtype by REGA Tool. To confirm sub-
type identification by REGA and NCBI genotyping tools, phylogenetic analysis with PhyML 3.0 online software 
was conducted75. Reference HIV-1 sequences of known genotype (subtypes and circulating recombinant forms 
(CRFs)), that were used in phylogenetic analysis, were retrieved from Los Alamos National Laboratory HIV 
Sequence Database’s compendium from the year 2016 (https://www.hiv.lanl.gov/content/sequence/NEWALIGN/
align.html). Phylogenetic tree for all examined and reference sequences was created in the PhyML 3.0 with the 
maximum likelihood (ML) method under the general time reversible nucleotide substitution model + gamma 
distribution of rates + proportion of invariable sites (GTR + G + I) with the gamma shape parameter and pro-
portion of invariable sites estimated from data (Supplementary Fig. S1). Tree topology was improved with both 
NNI (Nearest Neighbor Interchange) and SPR (Subtree Pruning and Regrafting) algorithms. Subsequently, all 
examined sequences were evaluated for recombination with the jumping profile hidden Markov model (jpHMM, 
http://jphmm.gobics.de/submission_hiv)76.
To determine HIV-1 coreceptor usage, all single proviral DNA env sequences coding for a V3 loop were ana-
lysed with the online geno2pheno algorithm (http://coreceptor.geno2pheno.org/index.php)77, which is one of the 
most widely accepted and used methods for genotypic prediction of viral tropism. In accordance with the current 
recommendations47 and results of prospective studies11,12,78, a false positive rate (FPR) of 10% was used to inter-
pret the clonal geno2pheno’s results, thus viruses were classified as non-R5 when V3 sequences displayed an FPR 
value ≤ 10%, (10% probability of classifying an R5 virus falsely as X4). Since the sensitivity of the geno2pheno 
method to detect X4 variants was shown to be lower for non-B subtypes than for subtype B67, sequences repre-
senting subtypes other than B were tested with PhenoSeq program, which is a newer tool developed to reliably 
predict the tropism of HIV-1 variants such as A, B, C, D, CRF01_AE and CRF02_AG (http://tools.burnet.edu.
au/phenoseq/)68.
Geno2pheno algorithm with FPR of 5.75 was also used to improve the specificity, and higher FPR values (of 
15% and 20%) were applied to increase the sensitivity for detection of non-R5 variants.
The number of ambiguous nucleotides in the obtained V3 coding fragments ranged from 0 to 7, thus all 292 
V3 sequences could be included in the genotypic tropism predictions, since it is not recommended to consider 
the V3 sequences with ≥8 ambiguous nucleotides in a coreceptor usage testing47.
Phylogenetic analyses and identification of clustered HIV-1 env sequences. Prior to phylogenetic 
analyses ClustalX algorithm was used to align 292 env sequences together with group M consensus sequence79. 
The alignment was manually edited using the BioEdit program80, and columns with gaps were removed. The 
GTR + G + I was selected as the best fitting nucleotide substitution model according to the Akaike and Bayesian 
Information Criterions (AIC, BIC) implemented in the jModeltest 2.1.9 software81. Under this model the nucle-
otide frequencies were: A = 0.4243, C = 0.1988, G = 0.1723, T = 0.2046; the substitution rates were: AC = 1.2416, 
AG = 3.9991, AT = 0.7674, CG = 0.5556, CT = 3.7929, GT = 1.0000; proportion of invariant = 0.165; and gamma 
shape parameter = 0.776.
Initially, transmission clusters were investigated with the PhyML 3.0 software75 using maximum likelihood 
(ML) method, under the selected GTR + G + I model, with the best of NNI and SPR algorithms for tree topology 
improvement. To evaluate branch supports of a phylogeny approximate likelihood ratio test (aLRT) values with 
nonparametric Shimodaira–Hasegawa–like (SH–like) algorithm were computed in the PhyML 3.0. The resulting 
ML phylogenetic tree and aligned sequence data were analysed with the Cluster Picker 1.2.5 software to identify 
monophyletic clusters based on specified thresholds for maximum pairwise genetic distances and aLRT support 
values82.
Additionally, a more robust Bayesian Metropolis coupled Markov chain Monte Carlo (MCMCMC) method 
was used to further verify the clusters. Two independent replicates of 50 million generations were run in MrBayes 
v.3.2.683 with sample frequency of 2500, under GTR + G + I model. A burn-in of 25% was used to summarize 
parameters and trees in the Bayesian approach. To control whether a sample from the posterior probability dis-
tribution was adequate, a plot of the generation vs the log probability was checked. The total effective sample size 
(ESS) values were above 200 for all parameters, average standard deviation of split frequencies decreased below 
0.01 after 11.9 million generations, and potential scale reduction factors (PSRFs) were reasonably close to 1.0 
indicating appropriate convergence. Finally, transmission clusters were identified when the following criteria 
were simultaneously met: i) aLRT value in ML method >0.9, ii) maximum within cluster pairwise genetic dis-
tance calculated in the Cluster Picker <3%, and iii) posterior probability in a Bayesian inference = 1. Such clusters 
are assumed to represent related transmission events between patients whose viral sequences are gathered within 
a single cluster. Phylogenetic trees were visualized in FigTree v.1.4.3.
Sequence data. All of the HIV-1 nucleotide sequences obtained in the study have been deposited in 
GenBank with the KT778123-KT778247 and MH627052-MH627218 accession numbers.
Statistical analysis. Comparisons of categorical variables between specified groups were performed with 
the Pearson’s Chi-square test. Two-tailed Fisher’s exact test was applied for binary variables and for variables 
with several possible categories to compare a specified category vs all other categories. The nonparametric 
Mann-Whitney U test was used for analysis of continuous variables. To examine the time trends in selected 
parameters, logistic and linear regression analyses with the year of HIV-1 diagnosis as a single predictor were 
performed for binary and continuous outcome variables, respectively. For the continuous outcome variables we 
present the slope of the linear effect of the diagnosis year. For the binary variables odds ratios per each addi-
tional year are provided. For greater comparability, for the binary variables we also calculated average prevalence 
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differences per year (average annual difference), by fitting linear regression model to annual average prevalences. 
All statistical analyses were performed using STATISTICA v13.1 enriched with a Medical Set (Statsoft, Warsaw, 
Poland), with the significance level defined by P < 0.05.
Ethical approval. The research was approved by the National Institute of Public Health – National Institute 
of Hygiene Bioethics Committee, Poland (no. 3/2007), and all procedures were performed in accordance with 
relevant guidelines and regulations. All collected samples and data were anonymous and coded. Written informed 
consent was obtained from study participants.
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